Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis stimulate in vitro angiogenesis and foster revascularization of ischemic limbs by Manetti, Mirko et al.
IJAE 
Vo l .  116 ,  n .  1  (Supp lem ent) :  109,  2011
© 2011 Firenze University Press 
ht tp://www.fupress .com/ijae
ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY
bone marrow-derived mesenchymal stem cells from early 
diﬀ use systemic sclerosis stimulate in vitro angiogenesis 
and foster revascularization of ischemic limbs
Mirko  Manetti1, Anna Franca  Milia2, Serena  Guiducci2, Eloisa  Romano2, Benedetta  Mazzanti3, 
Claudia  Ceccarelli2, Riccardo  Saccardi3, Marco  Matucci-Cerinic2, Lidia  Ibba-Manneschi1 
1 Department of Anatomy, Histology and Forensic Medicine, 2 Department of Biomedicine, Division of 
Rheumatology, 3Department of Hematology, University of Florence, Florence, Italy
Systemic sclerosis (SSc) is a chronic connective tissue disorder characterized by wide-
spread microangiopathy, lack of angiogenesis, and fi brosis. Bone marrow-derived mes-
enchymal stem cells (MSCs) produce and release high amounts of proangiogenic and 
antiapoptotic factors that inhibit apoptosis of endothelial cells under hypoxic conditions 
and promote the formation of capillary-like structures in vitro. In the present study, we 
characterized MSCs from SSc patients for the expression of factors implicated in MSC 
recruitment at sites of injury, angiogenesis, and fi brosis. We also analyzed whether SSc-
MSCs could modulate dermal microvascular endothelial cell (MVEC) angiogenesis in 
vitro. MSCs were obtained from 5 patients with early diff use SSc and 5 healthy donors. 
MSCs were expanded in culture and their phenotype was investigated by ﬂ ow cytom-
etry, CFU-F assay, and analysis of osteogenic/adipogenic diff erentiation. MSCs were 
stimulated with VEGF, TGFβ, or SDF-1. Transcript and protein levels of SDF-1 and its 
receptor CXCR4, VEGF, TGFβ1 and receptors TβRI/TβRII were evaluated by real-time 
RT-PCR, Western blotting, and confocal microscopy. VEGF, SDF-1, and TGFβ1 secre-
tion in culture supernatant was measured by ELISA. MVEC capillary morphogenesis 
was performed on Matrigel with the addition of MSC-conditioned medium. SSc- and 
healthy-MSCs showed no signifi cant diff erences in morphology, proliferation rate, CFU-
F colony formation or osteogenic/adipogenic diff erentiation. In SSc-MSCs, the basal 
expression of proangiogenic SDF-1/CXCR4 and VEGF was signifi cantly increased com-
pared to healthy-MSCs. SSc-MSCs constitutively released higher levels of SDF-1 and 
VEGF. SDF-1/CXCR4 were upregulated after VEGF stimulation, and CXCR4 redistribut-
ed from cytoplasm to cell surface. VEGF was increased by SDF-1 challenge. VEGF, TGFβ 
and SDF-1 stimulation upregulated TGFβ1, TβRI, and TβRII in SSc-MSCs. SSc-MSC-con-
ditioned medium showed a greater proangiogenic eff ect on MVECs than healthy-MSCs. 
Experiments with blocking antibodies demonstrated that MSC-derived cytokines were 
responsible for this potent proangiogenic eff ect. One patient who developed gangrene of 
the upper and lower limbs was treated with 3 intravenous infusions of expanded autol-
ogous MSCs. Areas of necrotic skin were reduced after the fi rst MSC infusion. After the 
third infusion, angiography showed revascularization of the patient’s extremities. Skin 
section analysis revealed cell clusters with tube-like structures, and angiogenic factors 
were strongly expressed. SSc-MSCs constitutively overexpress and release proangiogenic 
factors, and potentiate dermal MVEC angiogenesis in vitro. In SSc patients with severe 
peripheral ischemia, intravenous infusion of expanded autologous MSCs may foster the 
recovery of the vascular network.
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